A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

ClinicalTrials.gov ID: NCT01695044

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01695044. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic castration-resistant prostate cancer (mCRPC). One group comprises subjects who must have received at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel). The second group comprises subjects who are cytotoxic chemotherapy-naïve. Subjects who are cytotoxic chemotherapy-naïve must have received and progressed on-, be ineligible for, refused, have an intolerance to-, or not have access to Radium-223. Both groups of subjects must also have received and progressed on abiraterone acetate and/or enzalutamide. If a subject is unable to receive abiraterone acetate and/or enzalutamide, Sponsor approval is required for participation in the study. Subjects will receive up to eight doses of PSMA ADC approximately once every three weeks.

Study identification

NCT ID: NCT01695044
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Enrollment: 119 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

PSMA ADC Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2012 (Type not available)
Primary completion: Oct 2014 (Actual)
Completion: Feb 2015 (Actual)
Last update posted: Mar 24, 2017

2012 – 2015

United States locations

U.S. sites: 36
U.S. states: 25
U.S. cities: 35

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35205	—
Not listed	Tucson	Arizona	85724	—
Not listed	Burbank	California	91505	—
Not listed	Encinitas	California	92024	—
Not listed	Los Angeles	California	90024	—
Not listed	San Diego	California	92123	—
Not listed	Denver	Colorado	80218	—
Not listed	New Haven	Connecticut	06520	—
Not listed	Norwalk	Connecticut	06856	—
Not listed	Port Saint Lucie	Florida	34952	—
Not listed	Honolulu	Hawaii	96819	—
Not listed	Fairway	Kansas	66205	—
Not listed	New Orleans	Louisiana	70115	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Baltimore	Maryland	21205	—
Not listed	Rockville	Maryland	20850	—
Not listed	Boston	Massachusetts	02111	—
Not listed	Ann Arbor	Michigan	28109	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Omaha	Nebraska	68130	—
Not listed	Las Vegas	Nevada	89169	—
Not listed	Lake Success	New York	11042	—
Not listed	New York	New York	10065	—
Not listed	Rochester	New York	14642	—
Not listed	Stony Brook	New York	11794	—
Not listed	Huntersville	North Carolina	28078	—
Not listed	Raleigh	North Carolina	27607	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Pittsburgh	Pennsylvania	15232	—
Not listed	Providence	Rhode Island	02906	—
Not listed	Greenville	South Carolina	29605	—
Not listed	Myrtle Beach	South Carolina	29572	—
Not listed	Memphis	Tennessee	38120	—
Not listed	Dallas	Texas	75390	—
Not listed	Norfolk	Virginia	23502	—
Not listed	Seattle	Washington	98101	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01695044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 24, 2017 · Synced Nov 15, 2026